My GLP-1 stopped working. What now?

You lost 30 pounds in seven months. Then the scale stopped, and it has not moved in six weeks. The dose is the same, you are doing the same things, and it feels like the drug quit on you.

It almost certainly did not. The phrase "my GLP-1 stopped working" describes a real and frustrating experience, but it usually misdiagnoses the cause, and the wrong diagnosis leads to the wrong fix. Here is what the evidence actually shows.

A plateau is an equilibrium, not a failure

Weight loss stops when the forces pushing it down and the forces pushing it back up reach a balance. Both forces are real, and they are not the same size.

As you lose weight your body burns modestly fewer calories per day, roughly 20 to 30 fewer per kilogram lost. That much is widely known. What gets less attention is the other side: the drive to eat increases by roughly 100 calories per day per kilogram lost, more than three times the size of the metabolic effect. Appetite, not metabolism, does most of the work in stalling weight loss.

Source: Polidori D, Sanghvi A, Seeley RJ, Hall KD. How Strongly Does Appetite Counter Weight Loss? Quantification of the Feedback Control of Human Energy Intake. Obesity. 2016;24(11):2289-2295. Figures are population estimates; individual responses vary.

A GLP-1 works by suppressing that appetite drive. So the plateau arrives at the point where the accumulated hunger signal from the weight you have already lost exactly offsets what the medication is holding back. The drug is still doing its job at full strength. It has simply run out of margin.

The plateau is on schedule, and it is where the trials landed too

This is the part that reframes the whole problem: the pivotal trials plateaued too, at almost exactly the point most patients do.

• ◆ In STEP 5, weight loss on semaglutide 2.4 mg plateaued around week 60 and then held, ending at about 15.2% at week 104 versus 2.6% on placebo.
• ◆ In SELECT, weight loss continued for about 65 weeks and was then sustained all the way through week 208, four years on the medication, with no drift back up.
• ◆ In SURMOUNT-1, tirzepatide averaged 16.0%, 21.4% and 22.5% at 72 weeks on the 5, 10 and 15 mg doses.

So if you have been on treatment for a year and you are down 15%, you have not underperformed. You have matched the trial. The 30% loss you saw on social media was not the average result; it was the tail of the distribution.

Sources: Garvey WT, et al. Nat Med. 2022;28(10):2083-2091 (STEP 5); Ryan DH, et al. Nat Med. 2024;30(7):2049-2057 (SELECT); Jastreboff AM, et al. N Engl J Med. 2022 (SURMOUNT-1). Individual results vary.

GLP-1 tolerance is mostly a myth, and "drug holidays" are a bad idea

You will find plenty of content claiming your receptors have desensitized and that you need a washout period to reset them. Be skeptical. The one real study of GLP-1 tachyphylaxis, from 2011, involved nine healthy volunteers given an intravenous GLP-1 infusion across two meals four hours apart, and it found blunting of a single effect: the slowing of stomach emptying. That is an acute pharmacology experiment. It says nothing about whether a long-acting weekly analogue loses its weight effect over months.

Three lines of evidence argue directly against a tolerance model. Patients on continuous semaglutide in SELECT held their weight loss for four years, which receptors that had genuinely desensitized would not permit. The tirzepatide arm of SURMOUNT-4 lost a further 5.5% between weeks 36 and 88, after the point most patients would call a plateau. And most tellingly, when the medication is withdrawn the weight comes straight back, which only happens if the drug was still actively suppressing appetite at the moment you stopped.

That last point deserves its own numbers, because it is the strongest argument for staying on treatment through a plateau.

• ◆ In the STEP 1 extension, patients who stopped semaglutide regained about two thirds of their lost weight over the following 52 weeks, and most of the improvements in blood pressure and cholesterol drifted back toward baseline with it.
• ◆ In SURMOUNT-4, patients switched to placebo regained 14.0% while those who continued tirzepatide lost another 5.5%. Only 16.6% of the withdrawal group held on to most of their loss, against 89.5% of those who continued.

Sources: Nauck MA, et al. Diabetes. 2011;60(5):1561-1565; Wilding JPH, et al. Diabetes Obes Metab. 2022;24(8):1553-1564; Aronne LJ, et al. JAMA. 2024;331(1):38-48 (SURMOUNT-4). Individual results vary.

Four things worth checking, in this order

When a patient tells me the medication stopped working, this is the sequence I actually work through.

• ◆ Are you on the maximum dose you tolerate? A large share of patients plateau on an intermediate dose because a rough week during titration became a permanent stopping point. Higher doses produced later plateaus and larger losses in the trials. This is the most common and most fixable cause.
• ◆ Is adherence what you think it is? Missed weeks, a lapsed prescription, a pharmacy gap. Nationally, most patients without diabetes discontinue within 12 months, and a great deal of that is unintentional. Partial adherence looks exactly like a plateau from the inside.
• ◆ Would a different molecule do better? In SURMOUNT-5, the only head-to-head trial, tirzepatide produced 20.2% average weight loss against 13.7% for semaglutide 2.4 mg over 72 weeks. Plateauing at a good dose of semaglutide is a legitimate reason to discuss switching.
• ◆ Is this actually your endpoint? Sometimes the honest answer is that you have reached the result this medication produces for you, and the goal shifts from losing to keeping. That is a real clinical outcome, not a consolation prize, and it means staying on treatment rather than stopping.

Source for the head-to-head: Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26-36. Individual results vary.

Protect your muscle while you do it

Some of what you lose on a GLP-1 is lean tissue. How much is genuinely uncertain: published estimates range from under 15% to as much as 60% of total weight lost, and the spread is driven mostly by whether the study used DXA, MRI or bioimpedance rather than by real biological differences. Anyone quoting you one confident number is overstating what is known.

What is not controversial is the response. Adequate protein and consistent resistance training preserve lean mass during weight loss. The commonly cited target of roughly 1.2 to 1.5 grams of protein per kilogram of body weight per day during active loss is a reasonable consensus position, though it is extrapolated from general weight-loss research rather than proven in a GLP-1-specific trial. We would rather tell you that than dress up a guideline as settled science.

Range from Neeland IJ, Linge J, Birkenfeld AL. Diabetes Obes Metab. 2024;26(Suppl 4):16-27. Protein targets are consensus recommendations, not trial-validated dosing.

When a plateau is the argument for surgery

If you have escalated to the maximum tolerated dose, adherence is solid, you have tried the more effective molecule, and you are still meaningfully short of where you need to be for your knees or your sleep apnea or your diabetes, that is a conversation about surgery rather than a conversation about a higher dose. Bariatric surgery averages roughly 25 to 35% total body weight loss depending on the procedure, and it does not depend on an uninterrupted prescription.

This is where being one practice matters. Dr. Eduardo runs the medical weight-loss program and performs the surgery, so a plateau does not mean starting over with a new specialist who has no history with you. We can escalate the medication, switch it, or move to surgery as the evidence in your own chart directs. We prescribe branded, FDA-approved GLP-1s only, never compounded.

The bottom line

A plateau is your body reaching a new balance, not your medication wearing out. The evidence-based moves are to reach your maximum tolerated dose, verify adherence honestly, consider switching molecules, protect your muscle, and stay on treatment rather than taking a break that will cost you two thirds of your progress. If you have done all of that and you are still short of your goal, bring it in and let us look at the whole picture.